Portage Biotech Relaunches Subsidiary as Cyncado Therapeutics to Advance Next-Generation Immuno-Oncology Therapies

ADSCC Pioneers Clinical-Grade iPSCs, Advancing Regenerative Medicine in the Middle East

Atavistik Bio Collaborates with Pfizer to Advance Precision Allosteric Therapeutics

European Commission Approves Amivantamab-Lazertinib Combination for First-Line Treatment of EGFR-Mutated NSCLC

Sangamo Therapeutics Regains Rights to Hemophilia A Gene Therapy Following Pfizer Exit

Innovent Biologics Collaborates with Roche to Advance DLL3 ADC Candidate IBI3009

CARsgen Therapeutics Announces Positive Phase II Results for Satricabtagene Autoleucel in Gastric Cancer

IDEAYA Biosciences and Hengrui Pharma Collaborate on Novel DLL3-Targeting ADC for Precision Oncology

Novartis Reports Positive Phase III STEER Study Results for OAV101 IT in SMA Type 2 Patients

Digital Pathology Biomarkers: Transforming Precision Oncology Diagnostics and Treatment

DATROWAY® Approved in Japan for HR Positive, HER2 Negative Breast Cancer

FDA Approves Injectable Form of Opdivo, Offering Greater Convenience for Cancer Patients

Reliance Acquires Oncology Platform Karkinos for ₹375 Crore

FDA Approves TEVIMBRA® for First-Line Treatment of PD-L1-Positive Gastric and Gastroesophageal Junction Cancers

CSIR's 2024 Healthcare Breakthroughs: Advancing Cancer Detection, Genetic Disorders, and Neurodegenerative Disease Research

Home
/
update
/
details

Danaher Unveils Two New Diagnostic Innovation Centers to Revolutionize Precision Medicine Development

NextEdge Admin

19 Jul 2024

2 min 55 sec

Danaher Corporation , a global science and technology innovator, has launched two new CLIA and CAP-certified labs to expedite the development of Companion Diagnostics (CDx) and Complementary Diagnostics (CoDx). These labs are set to enhance Danaher's role in the innovation ecosystem by leveraging diagnostic technology to accelerate pharma translational research.

Julie Sawyer Montgomery, Danaher's Executive Vice President, highlighted the potential of these centers to speed up the market introduction of precision treatments, benefiting patients globally. Chief Scientific Officer Amit Agrawal emphasized the need for a streamlined approach in the pharmaceutical industry, reducing time-consuming assay transfers and contracts from biomarker validation to global deployment.

CDx tests identify whether a patient has sufficient levels of a specific protein to respond to a particular drug, while CoDx tests suggest the most beneficial type of therapy for a patient. These diagnostics are crucial in cancer treatment, significantly impacting patient prognosis.

Currently, the CDx and CoDx development process, from discovery to FDA approval, involves an average of 15 hand-offs. Danaher's new centers aim to drive efficiencies by minimizing these hand-offs and integrating multi-modal capabilities. With Danaher's extensive instrument base in over 30,000 hospitals across 120 countries, the company is well-positioned to facilitate the faster commercialization of personalized treatments.

The first lab, located in Newcastle, UK, will open in July and serve as a hub for collaborative research with leading pharmaceutical and academic institutions. Hosted by Leica Biosystems, a Danaher subsidiary, this lab will be situated in a state-of-the-art building on its campus. Another center of innovation in the United States, set to open later this year, will feature capabilities such as IHC, PCR, and immunoassay. The lab will utilize instrumentation from Danaher subsidiaries like Cepheid, Beckman Coulter Diagnostics, and Leica Biosystems, with additional modalities available through strategic partners.